Abstract:Abstract Background Esophageal cancer is highly prevalent in China, with esophageal squamous cell carcinoma (ESCC) being the predominant pathological type. However, the unclear pathogenesis of ESCC presents a challenge for identifying effective targets for molecular targeted therapy. RNA methylation is an important epigenetic regulatory mechanism that may play a key role in carcinogenesis. Our research has identified BCLAF1 as an oncogene in ESCC and contributes to cancer progression through an m6A-dependent mechanism. Methods Paraffin specimens and immunohistochemistry (IHC) were used to analyze the correlation between BCLAF1 and ESCC patient prognosis. Edu proliferation, clone formation, scratch, transwell, flow cytometry, and Seahorse assays were conducted to investigate the impact of BCLAF1 on ESCC cells. Subcutaneous xenograft tumor and lung metastasis models in nude mice were performed to assess the role of BCLAF1 in vivo. Immunofluorescence (IF), mass spectrometry, and co-immunoprecipitation analyses were utilized to study the binding relationship between YTHDF2 and BCLAF1. MeRIP-seq, RIP-seq, and RNA-seq analyses determined the RNA profile bound by YTHDF2. Rescue experiments were employed to examine the BCLAF1/YTHDF2/SIX1 axis. Results IHC and IF assays confirmed that BCLAF1 is mainly located in the cytoplasm of ESCC tissues and cells. BCLAF1 is associated with poor prognosis of ESCC patients and also promote malignant progression of ESCC in vitro and in vivo. Mechanistic studies have revealed that BCLAF1 can interact with the m6A reader protein YTHDF2 without affecting its stability, and could affect the binding capacity of YTHDF2 to downstream target SIX1 mRNA in an m6A-dependent manner. Knockdown of YTHDF2 can upregulate the level of SIX1 mRNA and promote aerobic glycolysis in ESCC, which could be rescued by the overexpression of BCLAF1. Conclusion BCLAF1 is a potent oncogene, and its encoded protein undergoes non-classical cytoplasmic translocation in ESCC. Cytoplasmic BCLAF1 directly interacts with YTHDF2 to regulate its function as a reader protein that recognizes and binds m6A sites, enhancing the stability of downstream targets such as SIX1 mRNA, activating the aerobic glycolysis pathway, and ultimately leading to malignant progression of ESCC.

MTHFD1L Confers a Poor Prognosis and Malignant Phenotype in Esophageal Squamous Cell Carcinoma by Activating the ERK5 Signaling Pathway

MTHFD2 Promotes Tumorigenesis and Metastasis in Lung Adenocarcinoma by Regulating AKT/GSK‐3β/β‐catenin Signalling

The Role of Mitochondrial Folate Enzyme MTHFD1L in Esophageal Squamous Cell Carcinoma

High Expression of Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) in Esophageal Squamous Cell Carcinoma and Its Clinical Prognostic Significance

MTHFD1L-Mediated Redox Homeostasis Promotes Tumor Progression in Tongue Squamous Cell Carcinoma

HIF1A-dependent Overexpression of MTFP1 Promotes Lung Squamous Cell Carcinoma Development by Activating the Glycolysis Pathway

Identification of MTHFD2 as a novel prognosis biomarker in esophageal carcinoma patients based on transcriptomic data and methylation profiling.

BCLAF1 drives esophageal squamous cell carcinoma progression through regulation of YTHDF2-dependent SIX1 mRNA degradation

The Transcription Factor LEF1 Promotes Tumorigenicity and Activates the TGF-β Signaling Pathway in Esophageal Squamous Cell Carcinoma

FLVCR1 Predicts Poor Prognosis and Promotes Malignant Phenotype in Esophageal Squamous Cell Carcinoma via Upregulating CSE1L

MiR-3682-3p promotes esophageal cancer progression by targeting FHL1 and activating the Wnt/β-catenin signaling pathway

METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway

MTA1 Promotes Tumorigenesis and Development of Esophageal Squamous Cell Carcinoma Via Activating the MEK/ERK/p90RSK Signaling Pathway

circ_0000592 facilitates the progression of esophageal squamous cell carcinoma via miR‐155‐5p/FZD5 axis

Data from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma Through NFκB–BMP Signaling Cross-talk

SLC35E2 Promoter Mutation As a Prognostic Marker of Esophageal Squamous Cell Carcinoma.

M6A reader YTHDF1 promotes malignant progression of laryngeal squamous carcinoma through activating the EMT pathway by EIF4A3

Defect of SLC38A3 Promotes Epithelial-Mesenchymal Transition and Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma.

339. CYTOPLASMIC TRANSLOCATION OF BCLAF1 REGULATES SIX1 MRNA STABILITY THROUGH YTHDF2 TO PROMOTE AEROBIC GLYCOLYSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA

METTL3 Facilitates Tumor Progression by COL12A1/MAPK Signaling Pathway in Esophageal Squamous Cell Carcinoma

Identification of LETM1 as a marker of cancer stem-like cells and predictor of poor prognosis in esophageal squamous cell carcinoma.